Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29657255 | 0.85 | TDP1 (0.34) | TDP1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL5141131 | 0.81 | TDP1 (0.40) | TDP1GPR35KDM4EMAPTMEN1 | |
| SCHEMBL23356575 | 0.78 | POLB (0.37) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL23356597 | 0.72 | BRD4 (0.46) | TDP1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL11729296 | 0.69 | PAX8 (0.38) | TDP1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29657208 | 0.69 | LMNA (0.36) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL23356593 | 0.68 | TDP1 (0.36) | TDP1GPR35KDM4EMAPTKMT2A | |
| SCHEMBL27762971 | 0.66 | ALDH1A1 (0.36) | TDP1GPR35KDM4EMAPTMEN1 | |
| SCHEMBL20502845 | 0.66 | TDP1 (0.36) | TDP1GPR35KDM4EMAPTMEN1 | |
| SCHEMBL15617625 | 0.65 | TDP1 (0.41) | TDP1GPR35KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147364-A1 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-05-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147364-A1 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | CBR1, POR, CAT | TDP1 2502/4885GPR35 4407/4885KDM4E 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.